Galderma’s EU-approved Emervel laugh line treatment to launch in US

Galderma has announced that its Emervel treatment for laugh lines has been approved by the US Food and Drug Administration.

The therapy will be sold in the US under the brand name Restylane for the treatment of laugh lines, or nasolabial folds, in patients over the age of 21. Two different versions will be made available for different patient groups.

Restylane Refyne has been approved for the treatment of moderate-to-severe facial wrinkles and folds, while Restylane Defyne is being offered for the treatment of moderate-to-severe deep facial wrinkles and folds.

These gels are manufactured with XpresHAn Technology, creating gels that offer a range of flexibility and support for varied patient needs. They have been shown to maintain effectiveness for the treatment of laugh lines for up to 12 months.

The Emervel range has been made available in Europe since 2010, with more than one million treatments sold worldwide to date.

Dr Kelly Huang, vice-president and general manager of the US aesthetic and corrective business of Galderma, said: "With these new brands, the Restylane family of products now represents the broadest offering of hyaluronic acid dermal fillers in the US."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.